VASCUGEN Trademark

Trademark Overview

On Tuesday, November 10, 2020, a trademark application was filed for VASCUGEN with the United States Patent and Trademark Office. The USPTO has given the VASCUGEN trademark a serial number of 90310251. The federal status of this trademark filing is REGISTERED as of Tuesday, June 18, 2024. This trademark is owned by Vascugen, Inc.. The VASCUGEN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Development of pharmaceutical preparations and medicines; medical and scientific research in the field of vascular and cardiovascular impairments; medical and scientific research in the field of allogeneic cell therapy; medical and scientific research in the field of regenerative medicine; providing medical and scientific research information in the field of regenerative medicine, vascular and cardiovascular impairments, and allogenic cell therapies; medical and scientific research in the field of treatment and prevention of critical limb ischemia, diabetic foot ulcer, peripheral artery disease, diabetic retinopathy, age-related macular degeneration, heart failure, stroke, traumatic brain injury, acute kidney injury, acute respiratory distress syndrome, bronchopulmonary dysplasia
vascugen

General Information

Serial Number90310251
Word MarkVASCUGEN
Filing DateTuesday, November 10, 2020
Status700 - REGISTERED
Status DateTuesday, June 18, 2024
Registration Number7422401
Registration DateTuesday, June 18, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 1, 2021

Trademark Statements

Goods and ServicesDevelopment of pharmaceutical preparations and medicines; medical and scientific research in the field of vascular and cardiovascular impairments; medical and scientific research in the field of allogeneic cell therapy; medical and scientific research in the field of regenerative medicine; providing medical and scientific research information in the field of regenerative medicine, vascular and cardiovascular impairments, and allogenic cell therapies; medical and scientific research in the field of treatment and prevention of critical limb ischemia, diabetic foot ulcer, peripheral artery disease, diabetic retinopathy, age-related macular degeneration, heart failure, stroke, traumatic brain injury, acute kidney injury, acute respiratory distress syndrome, bronchopulmonary dysplasia

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, January 9, 2021
Primary Code042
First Use Anywhere DateTuesday, May 31, 2022
First Use In Commerce DateTuesday, May 31, 2022

Trademark Owner History

Party NameVascugen, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMadison, WI 53717
Party NameVascugen, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMadison, WI 53717
Party NameVascugen, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMadison, WI 53717

Trademark Events

Event DateEvent Description
Friday, November 13, 2020NEW APPLICATION ENTERED
Saturday, January 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 19, 2021ASSIGNED TO EXAMINER
Thursday, April 29, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 12, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 1, 2021PUBLISHED FOR OPPOSITION
Tuesday, June 1, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 27, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, January 3, 2022SOU TEAS EXTENSION RECEIVED
Monday, January 3, 2022SOU EXTENSION 1 FILED
Monday, January 3, 2022SOU EXTENSION 1 GRANTED
Wednesday, January 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 24, 2022SOU TEAS EXTENSION RECEIVED
Friday, June 24, 2022SOU EXTENSION 2 FILED
Friday, June 24, 2022SOU EXTENSION 2 GRANTED
Tuesday, June 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 20, 2023SOU TEAS EXTENSION RECEIVED
Friday, January 20, 2023SOU EXTENSION 3 FILED
Friday, January 20, 2023SOU EXTENSION 3 GRANTED
Tuesday, January 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 13, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 13, 2023SOU EXTENSION 4 FILED
Thursday, July 13, 2023SOU EXTENSION 4 GRANTED
Saturday, July 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 1, 2023SOU TEAS EXTENSION RECEIVED
Friday, December 1, 2023SOU EXTENSION 5 FILED
Monday, December 11, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 11, 2023SOU EXTENSION 5 GRANTED
Tuesday, December 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 8, 2024USE AMENDMENT FILED
Wednesday, May 8, 2024TEAS STATEMENT OF USE RECEIVED
Friday, May 10, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, May 13, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, May 13, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 18, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 18, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

vascugen research field scientific medical medicine cell diabetic injury acute impairments